BPC

BPC-157 and TB-500 are the most discussed regenerative peptides in longevity circles. Here is what the animal research shows, how practitioners use them, and what you need to know about safety and sourcing.

BPC-157 / TB-500 (Moderate evidence) — two of the most discussed compounds in the intersection of regenerative medicine and longevity. Their appeal is straightforward: faster recovery from injuries means more consistent exercise, and consistent exercise is the single most impactful longevity intervention available. An athlete sidelined for months with a torn tendon or a weekend warrior nursing chronic tendinopathy cannot train, and the compounding effect of missed training weeks is significant over years and decades.

The challenge with discussing these peptides honestly is that the enthusiasm in the longevity community has dramatically outpaced the evidence base. BPC-157 has extensive and genuinely impressive animal research. TB-500 (synthetic thymosin beta-4) has solid wound healing data. But neither has a single published, peer-reviewed, randomized controlled trial in humans for injury recovery. This does not mean they do not work. It means we do not have the standard of evidence that normally precedes widespread adoption of a therapeutic compound.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. It was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb, who have published the majority of the research on this compound. Their work, spanning over two decades, has demonstrated healing effects across a remarkable range of tissue types in animal models.

A comprehensive review by Sikiric et al. published in Current Neuropharmacology documented BPC-157’s effects across multiple injury types:

The mechanism appears to involve modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), growth hormone receptor upregulation, and activation of the FAK-paxillin signaling pathway that governs cell migration and tissue repair. For the broader context of how peptides fit into longevity strategies, see our BPC-157 / TB-500 intervention page (Moderate evidence).

The critical caveat: All of this data comes from animal models. The dose translation from rats to humans is not straightforward, the injury models are artificially created, and the endpoints measured in animals do not always predict human outcomes. Dr. Sikiric’s group has conducted the vast majority of BPC-157 research, which means the findings have not been widely replicated by independent laboratories.